Synapse Biomedical, Inc. specializes in developing advanced medical devices aimed at reducing the reliance on mechanical ventilators for patients with spinal cord injuries. Operating primarily in the medical device market, the company serves healthcare providers and patients who require respiratory support. Its core product, the FDA-approved NeuRx Diaphragm Pacing System, is designed to enhance the quality of life for patients by enabling more natural breathing and reducing the need for invasive ventilators. The company generates revenue through the sale of its medical devices and related services. With a focus on innovation and patient care, Synapse Biomedical has also received an Emergency Use Authorization for its TransAeris DPS, further expanding its market reach. Supported by grants such as the $3 million Ohio Third Frontier Innovation Platform Program, the company is well-positioned for continued growth and commercialization of its cutting-edge technologies.

Keywords: Diaphragm pacing, spinal cord injury, ventilator reduction, NeuRx, TransAeris DPS, FDA-approved, respiratory support, medical devices, patient care, innovation.